tirzepatide and parkinson's disease Are GLP-1 diabetes drugs like Ozempic coming for disease? — Parkinson Secrets Frontiers | Metabolic Parkinson's disease
Description
The medication undergoes proteolytic degradation, and according to the FDA prescribing information, no dose adjustment is required for patients with hepatic impairment
doi: 10.1002/cncy.21860
This approach allowed for the integration of different types of evidence, broadening the understanding of the drugs clinical performance and safety profile in controlled and real-world settings
Where are the entry points in the fortified wall of the BBB
For example, semaglutide can sometimes cause side effects such as nausea or dehydration
